Chemotherapy for metastatic breast cancer

被引:66
作者
Mayer, Erica L. [1 ]
Burstein, Harold J. [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1016/j.hoc.2007.03.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gytotoxic chemotherapy is a mainstay of treatment for advanced breast cancer. Treatment of metastatic (also called stage IV, advanced, or recurrent) breast cancer is not considered curative. Rather, the goals of treatment with chemotherapy are to prolong survival, alleviate or prevent tumor-related symptoms or complications, and improve quality of life. While the purpose of chemotherapy is to prevent or alleviate symptoms, chemotherapy paradoxically carries considerable toxicities that cause substaritial symptoms in patients, notoriously including fatigue, nausea, vomiting, diarrhea, hair loss, mucositis, neutropemia, and neuropathy. Balancing the benefits and the side effects of chemotherapy is further complicated by the natural history of advanced breast cancer, which can be quite prolonged and typically involves multiple lines of chemotherapy, especially in patients whose tumors respond to treatment.
引用
收藏
页码:257 / +
页数:17
相关论文
共 75 条
[1]  
[Anonymous], 1986, J Clin Oncol, V4, P186
[2]  
[Anonymous], CLIN PRACT GUID ONC
[3]   Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women [J].
Bajetta, E ;
Procopio, G ;
Celio, L ;
Gattinoni, L ;
Della Torre, S ;
Mariani, L ;
Catena, L ;
Ricotta, R ;
Longarini, R ;
Zilembo, N ;
Buzzoni, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2155-2161
[4]  
BAKER LH, 1974, CANCER-AM CANCER SOC, V33, P513, DOI 10.1002/1097-0142(197402)33:2<513::AID-CNCR2820330228>3.0.CO
[5]  
2-H
[6]  
BESLIJA S, 2006, ANN ONCOL
[7]   Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial [J].
Blackstein, M ;
Vogel, CL ;
Ambinder, R ;
Cowan, J ;
Iglesias, J ;
Melemed, A .
ONCOLOGY, 2002, 62 (01) :2-8
[8]   Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].
Blum, JL ;
Jones, SE ;
Buzdar, AU ;
LoRusso, PM ;
Kuter, I ;
Vogel, C ;
Osterwalder, B ;
Burger, HU ;
Brown, CS ;
Griffin, T .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493
[9]   Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC) [J].
Bonneterre, J ;
Chevalier, B ;
Focan, C ;
Mauriac, L ;
Piccart, M .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1683-1691
[10]   Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer [J].
Bontenbal, M ;
Andersson, M ;
Wildiers, J ;
Cocconi, G ;
Jassem, J ;
Paridaens, R ;
Rotmensz, N ;
Sylvester, R ;
Mouridsen, HT ;
Klijn, JGM ;
van Oosterom, AT .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2257-2263